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ABSTRACT 
PURPOSE:  Radiotherapy is thought to produce clinical responses in 
cancer patients, through not only direct toxicity to cancer cells and 
supporting tumor stroma cells, but also through activation of 
immunological effectors.  More recently, radiotherapy (RT) has 
potentiated local and systemic effects of cancer immunotherapy (IT).  
However, combination regimens that maximize immunologic and clinical 
efficacy remain undefined.   
METHODS and MATERIALS:  We evaluated the impact of local RT on 
adenoviral-mediated vaccination against the colorectal cancer antigen 
GUCY2C (Ad5-GUCY2C) in a murine subcutaneous tumor model using 
mouse CT26 colon cancer cells (CT26-GUCY2C).  Immune responses were 
assessed by ELISpot and clinical responses were assessed by tumor size 
and incidence.  
RESULTS:  The specific sequence of tumor-directed RT preceding Ad5-
GUCY2C IT transformed inactive therapeutic Ad5-GUCY2C vaccination 
into a curative vaccine.  GUCY2C-specific T cell responses were amplified 
(p<0.05), tumor eradication maximized (p<0.01), and tumor volumes 
minimized (p<0.001) in mice whose tumors were irradiated prior to, 
compared to following, Ad5-GUCY2C vaccination.  The immunologic and 
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antitumor efficacy of Ad5-GUCY2C was amplified comparably by 
unfractionated (8 Gy x 1), or biologically equivalent doses of fractionated 
(3.5 Gy x 3), RT.  Antitumor effects of sequential RT and IT (RT-IT) 
depended on expression of GUCY2C by tumor cells and the adenoviral 
vaccine vector, and tumor volumes were inversely related to the 
magnitude of GUCY2C-specific T cell responses.  Moreover, mice cured of 
CT26-GUCY2C tumors by RT-IT exhibited long-lasting antigen-dependent 
protection, resisting tumors formed by GUCY2C-expressing 4T1 breast 
cancer cells inoculated 50 days after CT26 cells.   
CONCLUSIONS: Optimal sequencing of RT and IT amplifies antigen-
specific local and systemic immune responses, revealing novel acute and 
long-term therapeutic antitumor protection.  These observations 
underscore the importance of modality sequence optimization prior to 
initiating clinical trials of RT and IT to maximize immune and antitumor 
responses. 
 
Introduction 
Radiotherapy (RT) plays a central role in the management of most 
malignancies.  Historically, clinical responses following RT were 
attributed to radiation-induced mitotic catastrophe and apoptosis within 
cancer cells and to destruction of the tumor microenvironment [1,2].  
Beyond these toxicities, the therapeutic efficacy of RT may reflect, in part, 
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immunologic mechanisms.  The efficacy of RT in murine fibrosarcoma is 
impaired in mice that lack a normal T cell repertoire [3].  Similarly, 
patients with compromised immune systems exhibit markedly higher rates 
of local failures following RT compared to matched immunocompetent 
patients [4].  Further, tumor-directed RT in patients produces systemic 
immune responses associated with regression of non-irradiated 
metastases [5,6].  Moreover, prospective clinical trials revealed that 
tumor-directed RT adjuvanated systemic responses to immunotherapy 
(IT) [7,8]. 
In contrast to the established benefit of RT, the clinical efficacy of cancer 
vaccines generally has been unremarkable, particularly in patients with 
substantial volumes of disease.  For example, while colorectal cancer 
patients with minimal residual disease enjoy modest improvements in 
disease-free (HR = 0.76, p = 0.03) and overall survival (HR = 0.76, p = 
0.007) following vaccine therapy, clinical response rates in patients with 
advanced disease only approaches 1-2% [9].  This inefficacy reflects 
inhibitory immunologic mechanisms, which co-evolve during 
tumorigenesis, and quantitative tumor burden, which becomes 
immunologically insurmountable [10,11]. 
An emerging paradigm at the intersection of radiation-induced 
immunologic mechanisms and immune-based therapies suggests that RT 
can be systematically exploited to amplify local and systemic IT responses 
that overcome challenges in eradicating established tumors [8,12].  
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However, effective combinations of RT and IT, and their precise 
sequencing to maximize immune responses and tumor eradication have 
not been defined [13-15].  Here, we combined an adenoviral-based 
vaccine against the colorectal cancer antigen guanylyl cyclase C 
(GUCY2C) with different schedules of tumor-directed RT to augment local 
and systemic GUCY2C-specific immune responses, which produced acute 
and long-term antitumor protection. 
 
Methods and Materials 
Mice and immunizations.  Balb/c mice were obtained from the NCI Animal 
Production Program (Frederick, MD).  Animal protocols were approved by 
our Institutional Animal Care and Use Committee.  Vaccines included a 
second-generation adenovirus (Ad5) vector expressing the extracellular 
domain of mouse GUCY2C fused to the S1 CD4+ T helper epitope (Ad5-
GUCY2C) [16] and an Ad5-Her2 negative control vector.  Mice received 
1×108 IFU of adenovirus by IM injection of the anterior tibialis. 
Tumor models.  GUCY2C-deficient CT26-WT cells were from ATCC® (CRL-
2638).  Generation of mouse CT26-GUCY2C colorectal cancer cells was 
previously described [16].  4T1 mouse metastatic breast cancer cells 
(ATCC® CRL-2539) were transduced with pMSCV-Puro (Clontech) 
expressing a truncated GUCY2C-construct (GUCY2C1-461). Subcutaneous 
tumors were established by injection of 5x105 cells in the flanks or in the 
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left hind leg as indicated. Tumor volumes were calculated by measuring 
three orthogonal diameters and calculating volumes using: 4/3π × r1 × r2 × 
r3. 
Radiotherapy. Mice were anesthetized and irradiated using X-rays 
generated by a PanTak, 310 kVe X-ray machine. Each mouse was confined 
in a lead casing with its tumor-bearing left hind leg extended through an 
opening on the side to allow local tumor irradiation.  Biologically 
equivalent doses (BED) of radiation, calculated using an α\α of 10 and the 
formula BED = [(nd) + (nd2 ÷ α\α)], were administered as a single 8 Gy 
fraction (BED = 14.4 Gy) or as three fractions of 3.5 Gy delivered over one 
week (BED = 14.2 Gy). 
ELISpot.  IFNγ ELISpot assays were described previously [16]. Briefly, 
splenocytes (1x106) were stimulated with 10 µg/mL of peptide [GUCY2C254-
262 [17] or adenovirus DBP412-420 [18]] for 24 hours prior to spot 
development. 
Statistics.  Statistical differences between groups were analyzed with 
ANOVA and correlations between T cell responses and tumor volumes 
were analyzed with Pearson’s Coefficient using GraphPad Prism 
(GraphPad Software).  A p-value of <0.05 was considered statistically 
significant. 
 
Results 
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Ad5-GUCY2C IT or 8 Gy RT, alone, have limited effecacy against CT26-
GUCY2C tumors.  Balb/c mice bearing established GUCY2C-expressing 
CT26 (CT26-GUCY2C) subcutaneous leg tumors were immunized with 
Ad5-GUCY2C, or irradiated with 8 Gy 7 days after implantation (Fig. 1A).  
All inoculated mice developed subcutaneous tumors (incidence=100%).  
By day 28, the volumes of tumors from mice vaccinated with Ad5-GUCY2C 
(2,856.4 mm3 ± 229.2) were similar, while those from irradiated mice were 
smaller (1,385.4 mm3 ± 291.4 [8 Gy]; p <0.05), than tumor volumes from 
untreated control mice (2,519.6 mm3 ± 283.6; Fig. 1B). 
Radiotherapy prior to Ad5-GUCY2C amplified GUCY2C-specific T cell 
responses creating novel antitumor efficacy.  Balb/c mice bearing CT26-
GUCY2C subcutaneous leg tumors were treated with Ad5-GUCY2C 
immunization on day 7 after tumor inoculation, followed by 8 Gy 7 days 
later (Ad5-GUCY2C→RT; Fig. 2A).  Alternatively, tumor-bearing mice were 
treated with 8 Gy on day 7 after tumor inoculation, followed by Ad5-
GUCY2C immunization 7 days later (RT→Ad5-GUCY2C; Fig. 2A).  On day 
28 after tumor inoculation, T cell responses to GUCY2C were amplified 
about 6-fold in the RT→Ad5-GUCY2C group compared to Ad5-
GUCY2C→RT (151.7 ± 49.09 vs 23.9 ± 6.7 spots; p<0.05; Fig. 2B).  In 
contrast, Ad5-specific T cell responses were similar between treatment 
groups (356.3 ± 47.2 vs 423.7 ± 65.1 spots; p=NS; Fig. 2B).  Importantly, 
amplified immunologic responses produced by combining RT and IT 
created novel antitumor efficacy, eradicating some tumors (Fig. 2C).  
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Importantly, tumor eradication by RT→Ad5-GUCY2C was augmented 6-
fold compared to Ad5-GUCY2C→RT (60% vs 10% disease-free; p<0.01; 
Fig. 2C).  Moreover, tumor volumes for RT→Ad5-GUCY2C were reduced 
about 5-fold compared to Ad5-GUCY2CαRT (436 mm3 ± 234.9 vs 2,006.0 
mm3 ± 321.9; p <0.001; Fig. 2C). 
RT amplification of IT responses is independent of fractionation.  To 
determine if RT amplification of Ad5-GUCY2C vaccination was impacted 
by RT fractionation, cohorts were evaluated using a single dose of 8 Gy or 
a fractionated schedule of 3.5 Gy x 3 that had similar predicted biologic 
effects.  Indeed, 8 Gy and 3.5 Gy x 3 regimens comparably amplified 
GUCY2C-specific T cell responses (121.0 ± 29.3 vs 91.2 ± 25.2 spots; 
p=NS; Fig. 3A) and similarly improved tumor eradication (67% vs 60%; 
p=NS, Fig. 3B) and volumes (367.4 mm3 ± 196.8 vs 549.5 mm3 ± 275.2; 
p=NS; Fig. 3C). 
RT amplification of IT immunologic and tumor responses is GUCY2C-
specific.  Mice bearing CT26-GUCY2C tumors received 8 Gy radiation to 
the tumor on day 7 following tumor inoculation, and vaccination 7 days 
later with either Ad5-Her2 (control) or Ad5-GUCY2C.  On day 28 following 
tumor inoculation, GUCY2C-specific T cell responses were amplified 
(121.8 ± 35.1 vs 2.1 ± 1.6 spots; p<0.05), while Ad5-specific T cell 
responses were comparable (231.1 ± 19.6 vs 224.7 ± 7.7 spots; p=NS), in 
mice vaccinated with Ad5-GUCY2C compared to Ad5-Her2 (Fig. 4A).  
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Similarly, tumor eradication (70% vs 20%; p<0.05; Fig. 4B) and volumes 
(1,324.8 mm3 ± 424.2 vs 131.9 mm3 ± 88.0; p<0.01; Fig. 4C) were improved 
in mice vaccinated with Ad5-GUCY2C compared to Ad5-Her2.  
Conversely, mice bearing GUCY2C-deficient (CT26-WT) or GUCY2C-
expressing (CT26-GUCY2C) tumors received 8 Gy radiation to the tumor 
on day 7 following tumor inoculation, and received vaccination 7 days 
later with Ad5-GUCY2C.  On day 28 following tumor inoculation, GUCY2C-
specific T cell responses were amplified (161.7 ± 46.6 vs 50.3 ± 15.9 spots; 
p<0.05), while Ad5-specific T cell responses were comparable (353.4 ± 
75.5 vs 508.6 ± 88.3 spots; p=NS), in mice bearing CT26-GUCY2C, 
compared to those bearing CT26-WT, tumors (Fig. 4D).  Amplification of T 
cell responses in mice inoculated with CT26-GUCY2C, compared to CT26-
WT, cells reflects adjuvanation of immune responses by tumor cells 
undergoing radiation-induced immunogenic cell death.  Similarly, tumor 
eradication (60% vs 20%; p < 0.01; Fig. 4E) and volumes (415.5 mm3 ± 
199.2 vs 802.3 mm3 ± 210.3; p = 0.08; Fig. 4F) in mice bearing CT26-
GUCY2C tumors were improved compared to those bearing CT26-WT 
tumors.  Moreover, analysis of all CT26-GUCY2C-bearing mice across 
experimental regimens in Fig. 2-4 revealed an inverse relationship 
between GUCY2C (p=0.0016; Fig. 5A), but not Ad5 (p=NS; Fig. 5B), -
specific T cell responses and tumor volume. 
Sequential RT-IT induces long-term antitumor protection.  Naïve mice, or 
those cured of subcutaneous CT26-GUCY2C leg tumors by RT→Ad5-
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GUCY2C, were inoculated in the left flank with the Balb/c metastatic 
breast cancer cells (4T1-WT) and in the right flank with 4T1 cells 
expressing GUCY2C (4T1-GUCY2C) (Fig. 6A).  On day 17 after tumor 
inoculation, 4T1-WT and 4T1-GUCY2C tumor volumes were identical in 
naïve mice (519.9 mm3 ± 54.6 vs 517.3 mm3 ± 66.9; p=NS; Fig. 6B).  
However, 4T1-GUCY2C tumor volumes were reduced, compared to 4T1-
WT tumors, in mice previously cured of CT26-GUCY2C tumors (575.7 mm3 
± 121.2 vs 288.6 mm3 ± 98.39; p<0.001; Fig. 6C). 
 
Discussion 
RT is thought to induce immunogenic cancer cell death that, in part, 
activates tumor antigen-specific immune responses [19].  Combining RT 
with immunotherapies amplifies local and systemic antitumor activity 
beyond that of either modality alone [8,12].  Although molecular 
mechanisms underlying the synergy of combination RT and IT have been 
described [20], optimal sequencing of these treatments remains to be 
defined [13-15].  To our knowledge, this is the first study evaluating the 
impact of sequencing of combination RT and IT on immunologic responses 
and tumor indices.  Here, we demonstrate that immunologic responses to 
the colorectal cancer antigen GUCY2C are amplified, and associated with 
the creation of novel therapeutic tumor responses by irradiating tumors 
before, rather than after, vaccination. 
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In addition to the optimal scheduling of RT and IT, the most effective RT 
dose and fractionation remains to be defined.  Here, a dose of 8 Gy was 
selected because it caused a transient tumor growth delay that potentially 
could be amplified by an immune response.  In that context, moderate RT 
doses (~8 Gy) optimize tumor control and immunity [21].  Although large 
fraction sizes delivered to bone metastases or small visceral lesions is 
considered safe in clinical practice, 8 Gy delivered to large intra-
abdominal or intra-thoracic lesions, such as those encountered in patients 
with GI malignancies, may produce unacceptable side effects, since long 
term toxicity increases with fraction size.  Here, we evaluated whether 
fractionated RT with a similar biologically-equivalent dose, and potentially 
a more favorable side effect profile, could produce antitumor and immune 
responses that were comparable to a large single fraction of 
radiotherapy.  Indeed, 3.5 Gy x 3 produced similar increases in GUCY2C-
specific T cell responses and improvement in tumor eradication and 
volumes, compared to a single 8 Gy dose (Fig. 3).  Thus, the temporal 
relationship between RT and IT may be more important than RT dose or 
fractionation.  Indeed, clinical responses in a recent phase I trial 
evaluating three stereotactic RT dose cohorts prior to interleukin-2 
administration in patients with metastatic melanoma or renal cell 
carcinoma did not support an RT dose response [7].  
Ideally, tumor antigens would be expressed specifically by neoplastic 
tissues, thereby limiting on-target, off-site effects of immunotherapeutic 
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responses on normal tissues.  A variation on this theme exploits the 
structural and functional compartmentalization of central and mucosal 
immune systems by employing vaccines against antigens that are 
normally confined to intestinal epithelial cells and their derivative 
malignancies that would be considered foreign following systemic 
dissemination [22].  GUYC2C is normally expressed by enterocytes lining 
the small and large intestines [23-25] and is retained by nearly all 
colorectal tumors and their associated metastases [26-28], underscoring 
its utility as a marker for colorectal cancer staging [29] and making it an 
attractive vaccine target [22].  Thus, the dependence on GUCY2C 
expression for achieving synergy between RT and Ad5-GUCY2C in our 
therapeutic model was evaluated (Fig. 4).  Indeed, in mice challenged with 
cancer cells or receiving vaccine in which GUCY2C was absent, GUYC2C-
specific T cell responses and antitumor efficacy were reduced compared 
to mice challenged with cancer cells and vaccinated with adenovirus 
expressing GUCY2C.  Thus, GUCY2C antigen expression by tumors and 
the vaccine is critical to produce maximum T cell and antitumor 
responses.  The highly selective expression of GUCY2C within intestinal 
epithelia [23,24,30] and the near universal over-expression of GUCY2C by 
intestinal malignancies, combined with the safety and efficacy of 
GUCY2C-targeted immunotherapies [16,17,31,32], make GUCY2C an ideal 
target for combined RT-IT therapy in patients. 
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The abscopal effect, which occurs when RT induces immune-mediated 
regression of tumors beyond the irradiation field, has emerged as a key 
focus of intense study in model systems and patients [5,7,8].  Abscopal 
regression depends on the ability to generate local immunologic 
responses that translate systemically to tumors anatomically separated 
from, but coincident in time with, the irradiated tumor.  While bridging this 
spatial continuum to treat coincident metastases, the ability of the 
abscopal effect to create memory responses that endure temporally to 
provide long-term antitumor protection over time has not yet been 
defined.  Here, mice previously cured of subcutaneous CT26-GUYC2C 
tumors by RT→Ad5-GUCY2C were challenged 50 days after the first 
cancer cell inoculation with an unrelated (breast) tumor cell line 
engineered to express GUCY2C (4T1-GUCY2C).  Mice cured of CT26-
GUCY2C tumors by sequential RT-IT resisted 4T1-GUCY2C, but not 4T1-
WT (control), tumor growth.  These observations suggest that sequential 
RT-IT induces long-term GUCY2C-specific immune memory, supporting 
the use of RT-IT in the curative setting to provide systemic surveillance 
against metastatic recurrences. 
Sequential RT-IT approaches ultimately will require surrogate biomarkers 
of efficacy that predict clinical responses, and recent guidelines focus on 
detection and quantification of antigen-specific T cells [33].  In that 
context, T cell responses to HPV E6 and E7 antigens were associated with 
a complete resolution of vulvar intraepithelial neoplasia in patients 
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vaccinated with those proteins [34].  However, it remains unknown if 
minimum T cell responses are required to produce clinical effects.  Here, 
quantification of T cell responses in individual tumor-bearing mice across 
all treatment regimens enabled evaluation of the relationship between T 
cell and tumor responses.  Indeed, GUCY2C, but not Ad5, -specific T cell 
responses strongly correlated with tumor responses (Fig. 5).  In these 
analyses, independence of Ad5-specific T cell and tumor responses 
confirms that the observed relationship reflects treatment-induced tumor 
responses, rather than variations in immunocompetency of individual 
tumor-bearing animals.  Moreover, these analyses suggest T cell 
response thresholds are required for tumor responses.  Thus, the majority 
(73%) of mice that produced less than 60 GUCY2C-specific T cells/106 
splenocytes experienced progressive disease.  In contrast, the majority 
(77%) of mice that exceeded 60 GUCY2C-specific T cells/106 splenocytes 
were cured of their tumors.  If confirmed in patients, T cell response 
thresholds as a surrogate marker for clinical responses to sequential RT-
IT could accelerate the development of new therapeutic paradigms, 
offering patients an opportunity to receive additional treatments before 
disease progression. 
While RT-IT produced favorable murine outcomes, correlating with 
immunological responses, limitations in translating animal studies to 
clinical practice suggest that clinical comparisons of RT-IT regimens are 
required to maximize patient outcomes. Spontaneously metastatic tumors 
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are rare in mice [35], limiting animal studies to orthotopic or ectopic 
models of metastasis. Xenogeneic systems are not feasible for these 
studies, because intact immunity is required to produce immunological 
responses following RT-IT. Avatars - mice expressing human GUCY2C, 
containing a human immune system and human colorectal cancer 
xenografts - would be ideal for testing GUCY2C immunotherapy [36], but 
these systems are not yet developed.  
The present study reveals a relationship between the sequence of RT and 
IT and immunologic and antitumor efficacy.  Unfractionated or 
fractionated RT prior to IT with a single dose of an adenoviral GUCY2C-
based vaccine amplifies antigen-specific T cell responses creating novel 
antigen-dependent antitumor responses.  Generally, these observations 
suggest the importance of careful assessment of sequencing modalities in 
clinical trials integrating RT and IT.  More specifically, these studies 
highlight the translational potential for sequential RT-IT employing 
GUCY2C as an antigen target.  Indeed, an ongoing phase I clinical trial is 
evaluating the immunogenicity of Ad5-GUCY2C in patients with colon 
cancer.  Pending positive outcomes in that study, the results presented 
here can be directly translated to patients with esophageal, gastric and 
rectal cancer, which express GUCY2C as part of their pathophysiology 
[26,37] and which frequently include tumor-directed RT as standard of 
care [38-40]. 
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Figure Legends 
Figure 1.  Individual Ad5-GUCY2C and 8 Gy modalities are therapeutically 
ineffective.  (A) Mice challenged with CT26-GUCY2C cells were observed 
(n=10), vaccinated with Ad5-GUCY2C (n=10), or irradiated with 8 Gy (n=5) 
on day 7.  (B) All mice developed tumors.  Vaccinated mice exhibited 
growth rates similar to control.  Tumors in irradiated mice were 
significantly smaller than controls. 
Figure 2.  Radiotherapy prior to Ad5-GUCY2C amplifies GUCY2C-specific 
T cells and reduces tumor growth.  (A) Mice challenged with CT26-
GUCY2C cells (day 0) were treated with Ad5-GUCY2C or 8 Gy on day 7 
and then treated with the opposing modality on day 14, generating two 
cohorts: Ad5→RT (n=10) and RT→Ad5 (n=10).  Tumor volumes and 
GUCY2C-specific T cell responses were quantified on day 28.  (B) T cell 
responses to GUCY2C were increased in the RT→Ad5 cohort compared to 
Ad5→RT.  There was no difference in Ad5-specific T cell responses. 
Tumor cure rates (C) were increased and volumes (D) were decreased 
following RT→Ad5 compared to Ad5→RT. 
Figure 3.  Unfractionated or fractionated RT preceding Ad5-GUCY2C 
produces similar immunologic and antitumor responses.  (A) Mice 
challenged with CT26-GUCY2C cells (day 0) were observed (n=10), 
treated with 8 Gy on day 7 (n=10), or treated with 3.5 Gy on days 7, 10, and 
13 (n=10).  Irradiated mice received Ad5-GUCY2C on day 14. GUCY2C-
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specific and Ad5-specific T cell responses (B), tumor cure rates (C), and 
volumes (D) were similar between unfractionated and fractionated RT 
treatment groups. 
Figure 4.  GUCY2C is required for RT-amplified therapeutic vaccination.  
(A-C) Mice challenged with CT26-GUCY2C cells (day 0) were irradiated 
with 8 Gy on day 7 followed by Ad5-Her2 (n=5) or Ad5-GUCY2C (n=10) on 
day 14, and immune and antitumor responses quantified on day 28.  (A) 
GUCY2C-specific, but not Ad5-specific, T cell responses were amplified in 
mice vaccinated with Ad5-GUCY2C compared to Ad5-Her2 vaccine.  
Tumor cure rates were increased (B) and volumes were decreased (C) in 
mice vaccinated with Ad5-GUCY2C, compared to Ad5-Her2.  (D-F) Mice 
challenged with CT26-WT (n=10) or CT26-GUCY2C (n=10) cells (day 0) 
were irradiated with 8 Gy on day 7, vaccinated with Ad5-GUCY2C on day 
14, and immune and antitumor responses quantified on day 28.  (D) 
GUCY2C-specific, but not Ad5-specific, T cell responses were amplified in 
mice challenged with CT26-GUCY2C cells compared to mice challenged 
with CT26-WT cells.  Tumor cure rates were increased (E) and volumes 
were decreased (F) in mice challenged with CT26-GUCY2C, compared to 
CT26-WT, cells. 
Figure 5.  Tumor volumes correlate with GUCY2C, but not Ad5, -specific T 
cell responses.  Antigen-specific immune responses by individual mice 
were rank-ordered for GUCY2C (A) or Ad5 (B) from animals across all 
experiments employing CT26-GUCY2C tumors, regardless of treatment 
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regimen.  There was a significant association between GUCY2C-specific 
(A), but not Ad5-specific (B), T cell responses and tumor volumes. 
Figure 6.  Mice cured of CT26-GUCY2C tumors by sequential RT-IT exhibit 
GUCY2C-dependent long-term antitumor protection.  (A) Mice were 
challenged with CT26-GUCY2C cells and cured with 8 Gy followed by 
therapeutic Ad5-GUCY2C vaccination.  Fifty days following initial tumor 
challenge, cured and naïve mice were challenged with 4T1-WT in the left 
flank and 4T1-GUCY2C in the right flank and tumor volumes were 
measured longitudinally.  (B) 4T1-WT and 4T1-GUCY2C tumor growth was 
equivalent in naïve mice.  (C) In contrast, 4T1-GUCY2C tumor growth was 
inhibited, compared to 4T1-WT tumors, in mice previously cured of CT26-
GUCY2C tumors. 
